



NDA 022544/S-027

APPROVAL LETTER

Almatica Pharma LLC
Attention: Ayse Baker
Vice President of Regulatory Affairs
44 Whippany Road, Suite 300
Morristown, NJ 07960

Dear Ms. Baker:

Please refer to your Supplemental New Drug Application (sNDA) dated and received March 18, 2021, and your amendment, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Gralise (gabapentin) Tablets.

This "Changes Being Effected in 30 days" supplemental new drug application provides for the addition of [REDACTED] ^{(b) (4)} as an alternate drug product manufacturing facility for Gralise (gabapentin) Tablets, 300 mg and 600 mg.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELS

Submit final printed carton and container labels that are identical to enclosed carton and container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 022544/S-027.**” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Teicher Agosto, Regulatory Business Process Manager, at (240) 402 - 3777.

Sincerely,

{See appended electronic signature page}

Gurpreet Gill-Sangha, Ph.D
Branch Chief, B3
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Carton and Container Labeling



Gurpreet
Gill Sangha

Digitally signed by Gurpreet Gill Sangha

Date: 9/16/2021 03:05:18PM

GUID: 5135f2ad000117842392c50c36c7f28a